Clinical Trials Logo

Androgenetic Alopecia clinical trials

View clinical trials related to Androgenetic Alopecia.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05129254 Withdrawn - Clinical trials for Androgenetic Alopecia

Thulium Laser and Topical Platelet Rich Plasma (PRP) vs. PRP Injection for the Treatment of Male Androgenetic Alopecia

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

The objective of this clinical study is to compare the safety and efficacy of a laser and topically applied platelet-rich plasma vs. platelet rich plasma injection in the treatment of male-pattern hair loss. Participating subjects will receive up to four (4) monthly treatments and will have a 12 month follow-up period.

NCT ID: NCT04882969 Withdrawn - Clinical trials for Androgenetic Alopecia

Thulium Laser and KeraFactor for the Treatment of Androgenetic Alopecia

Start date: September 1, 2021
Phase: N/A
Study type: Interventional

The objective of this clinical study is to assess the safety and efficacy of using a laser and hair growth factors in the treatment of male-pattern hair loss. Participating subjects will receive up to two (2) treatments per month for 6 months with the laser and post-treatment topically applied hair growth factors and will have a 6 month follow-up period.

NCT ID: NCT04379583 Withdrawn - Clinical trials for Androgenetic Alopecia

HairDx Analytical Validation Study

Start date: June 15, 2020
Phase:
Study type: Observational

The HairDx Test reports genetic variants associated with the development of FPHL.

NCT ID: NCT04368897 Withdrawn - COVID-19 Clinical Trials

In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity

Start date: May 1, 2020
Phase:
Study type: Observational

The COVID-19 Androgen Sensitivity Test is a non-invasive In-Vitro Diagnostic device that utilizes Next Generation Sequencing Technology (NGS). The results of the test are used by a physician to assess the risk of developing severe symptoms following COVID-19 infection, The COVID-19 Androgen Sensitivity Test requires a health care professional to collect a DNA sample using an FDA cleared DNA sample collection kit.

NCT ID: NCT03852992 Withdrawn - Clinical trials for Androgenetic Alopecia

Laser Assisted Delivery of Minoxidil in Androgenetic Alopecia

Start date: September 30, 2022
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the safety and efficacy of fractionated ablative 10,600nm CO2 laser assisted delivery of 2% minoxidil solution in the treatment of MPHL. In this cohort study, patients will randomly be assigned stand-alone laser treatment, laser assisted drug delivery of minoxidil 2% solution, and laser assisted drug delivery of minoxidil 2% solution plus at home 5% minoxidil treatment. The primary endpoints will be to assess the change from baseline in investigator and subject Hair Growth Assessments (HGA), Hair Growth Index (HGI) and the Hair Growth Satisfaction Scale (HGSS) over 8-12 weeks in each of the three groups. The secondary endpoints will be expert assessment of hair density from baseline and evaluation of safety and adverse events, and pharmacokinetic (PK) data.

NCT ID: NCT03048461 Withdrawn - Clinical trials for Androgenetic Alopecia

The Effect of Platelet-rich Plasma in Subjects With Androgenetic Alopecia

Start date: June 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effect of autologous platelet-rich plasma (PRP) in the treatment of androgenetic alopecia. This is a randomized clinical trial to evaluate the effect of autologous platelet rich plasma in subjects with moderate androgenetic alopecia. Approximately 30 subjects will be randomized into the study. The study is designed as an 18-month study consisting of 2 phases. This study was a pilot study designed to determine feasibility of this procedure. Subjects currently living in the Chicago metropolitan area and meet inclusion/exclusion criteria will be considered for enrollment.

NCT ID: NCT02486848 Withdrawn - Clinical trials for Androgenetic Alopecia

Minoxidil Dose Response Study in Females Identified Through IVD Testing as Non-Responders to 5% Topical Minoxidil

Start date: June 2016
Phase: N/A
Study type: Interventional

5% topical minoxidil is the maximum dosage approved by the US FDA for the treatment of female pattern hair loss. While topical minoxidil exhibits a good safety profile, the efficacy in the overall population is relatively low i.e., 30-40% re-grow hair. The primary purpose of this study is to assess if a higher dosage of topical minoxidil dosage (15%) will increase the number of responders among female subjects that have been identified through IVD testing as non-responders to 5% topical minoxidil.